Intelligence · Clinical Pipeline
Kura Oncology Pipeline
All ClinicalTrials.gov programs at Kura Oncology — phase, modality, and trial IDs.
- Programs
- 13
Quick answer
Kura Oncology has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology
Relapsed and/or refractory Acute Myeloid Leukemia
1 trial -
Darlifarnib
Kura Oncology
Solid Tumors With HRAS Alterations
1 trial -
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Kura Oncology
Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma
1 trial -
KO-947
Kura Oncology
Advanced Malignant Neoplasm
1 trial -
Tipifarnib
Kura Oncology
NSCLC
1 trial -
Tipifarnib
Kura Oncology
Advanced Solid Tumor
1 trial -
Venetoclax
Kura Oncology
Acute Myeloid Leukemia
1 trial -
Ziftomenib
Kura Oncology
Relapsed/Refractory KMT2A-r Acute Leukemia
1 trial -
Ziftomenib
Kura Oncology
Acute Myeloid Leukemia
1 trial -
Ziftomenib
Kura Oncology
AML
1 trial -
Ziftomenib
Kura Oncology
KMT2A-rearranged
1 trial -
Ziftomenib
Kura Oncology
Refractory Acute Leukemia
1 trial -
ziftomenib
Kura Oncology
Gastrointestinal Stromal Tumor (GIST)
1 trial
Frequently asked questions
How many pipeline programs does Kura Oncology have?
13 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs